Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference

References

• FahnSOakesDShoulsonILevodopa and the progression of Parkinson’s diseaseN Engl J Med2004351242498250815590952
   PubMed Web of Science ®Google Scholar
• BirkmayerWHornykiewiczO[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]Wien Klin Wochenschr19617378778813869404
   PubMedGoogle Scholar
• CotziasGCPapavasiliouPSGelleneRModification of Parkinsonism – chronic treatment with L-dopaN Engl J Med196928073373454178641
   PubMed Web of Science ®Google Scholar
• MüllerTTolcapone in the management of Parkinson’s diseaseAging Health200625709720
   Google Scholar
• RuottinenHMRinneUKCOMT inhibition in the treatment of Parkinson’s diseaseJ Neurol199824511 Suppl 32534
   Web of Science ®Google Scholar
• CeravoloRPicciniPBaileyDLJorgaKMBrysonHBrooksDJ18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s diseaseSynapse200243320120711793426
   PubMed Web of Science ®Google Scholar
• RussHMüllerTWoitallaDRahbarAHahnJKuhnWDetection of tolcapone in the cerebrospinal fluid of parkinsonian subjectsNaunyn Schmiedebergs Arch Pharmacol1999360671972010619191
   PubMed Web of Science ®Google Scholar
• SawleGVBurnDJMorrishPKThe effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson’s diseaseNeurology1994447129212978035933
   PubMed Web of Science ®Google Scholar
• HauserRAPanissetGAbbruzzeseGManzioneLDronamrajuRKakariekaAImproved symptom control with fixed dose levodopa/carbidopa/entacapone versus conventional levodopa/carbidopa as first-line levodopa therapy in early Parkinson’s disease patientsMov Disord200823Suppl 1208
   Web of Science ®Google Scholar
• OlanowCWKieburtzKSternMDouble-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson diseaseArch Neurol200461101563156815477510
   PubMedGoogle Scholar
• MüllerTErdmannCMuhlackSBremenDPrzuntekHWoitallaDInhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levelsMov Disord200621333233616211593
   PubMed Web of Science ®Google Scholar
• OlanowCWObesoJAPulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitorsNeurology20005511 Suppl 4S72S7711147513
   PubMed Web of Science ®Google Scholar
• MüllerTRussHLevodopa, motor fluctuations and dyskinesia in Parkinson’s diseaseExpert Opin Pharmacother20067131715173016925499
   PubMed Web of Science ®Google Scholar
• RiedererPGerlachMMüllerTReichmannHRelating mode of action to clinical practice: dopaminergic agents in Parkinson’s diseaseParkinsonism Relat Disord200713846647917919963
   PubMed Web of Science ®Google Scholar
• NyholmDPharmacokinetic optimisation in the treatment of Parkinson’s disease : an updateClin Pharmacokinet200645210913616485914
   PubMed Web of Science ®Google Scholar
• MeilerBAndrichJMüllerTRapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusionMov Disord200823114514617987653
   PubMed Web of Science ®Google Scholar
• OlanowCWStocchiFCOMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications?Neurology2004621 Suppl 1S72S8114718683
   PubMed Web of Science ®Google Scholar
• SmithLAJacksonMJAl BarghouthyGMultiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primatesMov Disord200520330631415490461
   PubMed Web of Science ®Google Scholar
• StocchiFVaccaLRuggieriSOlanowCWIntermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyArch Neurol200562690591015956161
   PubMedGoogle Scholar
• LeeMSKimHSChoEKLimJHRinneJOCOMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s diseaseNeurology200258456456711865133
   PubMed Web of Science ®Google Scholar
• WoitallaDKarwaszRMüllerTPrzuntekHKuhnWThe activity of catechol-O-methyltransferase in parkinsonian patients with “on-off fluctuations”J Neural Transm2000107110511110809408
   PubMed Web of Science ®Google Scholar
• MuhlackSWoitallaDWelnicJTwiehausSPrzuntekHMüllerTChronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s diseaseNeurosci Lett2004363328428715182961
   PubMed Web of Science ®Google Scholar
• MüllerTWoitallaDSaftCKuhnWLevodopa in plasma correlates with body weight of parkinsonian patientsParkinsonism Relat Disord20006317117310817957
   PubMed Web of Science ®Google Scholar
• MüllerTErdmannCBremenDImpact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patientsClin Neuropharmacol2006292616716614536
   PubMed Web of Science ®Google Scholar
• MüllerTWoitallaDGoetzeOErdmannCEntacapone improves absorption of a coadministered salt in patients with Parkinson’s diseaseMov Disord200823101458146118546331
   PubMed Web of Science ®Google Scholar
• KortejarviHUrttiAYliperttulaMPharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination ratesEur J Pharm Sci200730215516617187967
   PubMed Web of Science ®Google Scholar
• ForsbergMLehtonenMHeikkinenMSavolainenJJarvinenTMannistoPTPharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the ratJ Pharmacol Exp Ther2003304249850612538800
   PubMed Web of Science ®Google Scholar
• ForsbergMMHuotariMSavolainenJMannistoPTThe role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administrationEur J Pharm Sci200524550351115784340
   PubMed Web of Science ®Google Scholar
• GoetzeOWieczorekJMüllerTPrzuntekHSchmidtWEWoitallaDImpaired gastric emptying of a solid test meal in patients with Parkinson’s disease using 13C-sodium octanoate breath testNeurosci Lett2005375317017315694254
   PubMed Web of Science ®Google Scholar
• GoetzeONikodemABWiezcorekJPredictors of gastric emptying in Parkinson’s diseaseNeurogastroenterol Motil200618536937516629864
   PubMed Web of Science ®Google Scholar
• LennernasHModeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humansCurr Drug Metab20078764565717979653
   PubMed Web of Science ®Google Scholar
• ThwaitesDTAndersonCMH+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestineExp Physiol200792460361917468205
   PubMed Web of Science ®Google Scholar
• MannistoPTCatechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitorsAdv Pharmacol1998423243289327906
   PubMedGoogle Scholar
• MüllerTErdmannCMuhlackSPharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s diseaseJ Neural Transm2006113101441144816604302
   PubMed Web of Science ®Google Scholar
• MüllerTKolfKAnderLWoitallaDMuhlackSCatechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson diseaseClin Neuropharmacol200831313414018520980
   PubMed Web of Science ®Google Scholar
• MüllerTAnderLKolfKWoitallaDMuhlackSComparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s diseaseJ Neural Transm2007114111457146217564755
   PubMed Web of Science ®Google Scholar
• FabbriniGJuncosJLMouradianMMSerratiCChaseTN3-O-methyldopa and motor fluctuations in Parkinson’s diseaseNeurology19873758568593574690
   PubMed Web of Science ®Google Scholar
• Soares-da-SilvaPParadaASerraoPThe O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylaseBrain Res20008631229329710773187
   PubMed Web of Science ®Google Scholar
• ArnstenAFLiBMNeurobiology of executive functions: catecholamine influences on prefrontal cortical functionsBiol Psychiatry200557111377138415950011
   PubMed Web of Science ®Google Scholar
• MüllerTRole of homocysteine in the treatment of Parkinson’s diseaseExpert Rev Neurother20088695796718505360
   PubMedGoogle Scholar
• Ben ShlomoYMarmotMGSurvival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?J Neurol Neurosurg Psychiatry19955832932997897409
   PubMed Web of Science ®Google Scholar
• GorellJMJohnsonCCRybickiBAParkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990Neurology19944410186518687936238
   PubMed Web of Science ®Google Scholar
• NakasoKYasuiKKowaHHypertrophy of IMC of carotid artery in Parkinson’s disease is associated with L-DOPA, homocysteine, and MTHFR genotypeJ Neurol Sci200320712192312614923
   PubMed Web of Science ®Google Scholar
• O’SuilleabhainPESungVHernandezCElevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associationsArch Neurol200461686586815210523
   PubMedGoogle Scholar
• OzerFMeralHHanogluLPlasma homocysteine levels in patients treated with levodopa: motor and cognitive associationsNeurol Res200628885385817288745
   PubMed Web of Science ®Google Scholar
• ZoccolellaSLambertiPIlicetoGPlasma homocysteine levels in L-dopa-treated Parkinson’s disease patients with cognitive dysfunctionsClin Chem Lab Med200543101107111016197306
   PubMed Web of Science ®Google Scholar
• Hassin-BaerSCohenOVakilEPlasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complicationsClin Neuropharmacol200629630531117095893
   PubMed Web of Science ®Google Scholar
• O’SuilleabhainPEOberleRBartisCDeweyRBJrBottiglieriTaz-ArrastiaRClinical course in Parkinson’s disease with elevated homocysteineParkinsonism Relat Disord200612210310716368256
   PubMed Web of Science ®Google Scholar
• MillerJWSelhubJNadeauMRThomasCAFeldmanRGWolfPAEffect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin statusNeurology20036071125112912682318
   PubMed Web of Science ®Google Scholar
• WoitallaDKuhnWMüllerTMTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson’s diseaseJ Neural Transm Suppl200468152015354385
   PubMedGoogle Scholar
• MüllerTKuhnWTolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patientsEur J Clin Pharmacol200662644745016758261
   PubMed Web of Science ®Google Scholar
• NissinenENissinenHLarjonmaaHThe COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult ratsJ Neural Transm200511291213122115614425
   PubMed Web of Science ®Google Scholar
• OstremJLKangGASubramanianIThe effect of entacapone on homocysteine levels in Parkinson diseaseNeurology2005648148215851757
   PubMed Web of Science ®Google Scholar
• ZesiewiczTAWeckerLSullivanKLMerlinLRHauserRAThe controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin statusClin Neuropharmacol200629310611116772808
   PubMed Web of Science ®Google Scholar
• LambertiPZoccolellaSIlicetoGEffects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson’s disease patientsMov Disord2005201697215390046
   PubMed Web of Science ®Google Scholar
• ValkovicPBenetinJBlazicekPValkovicovaLGmitterovaKKukumbergPReduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patientsParkinsonism Relat Disord200511425325615878587
   PubMed Web of Science ®Google Scholar
• ZoccolellaSLambertiPArmeniseEPlasma homocysteine levels in Parkinson’s disease: role of antiparkinsonian medicationsParkinsonism Relat Disord200511213113315734674
   PubMed Web of Science ®Google Scholar
• IsobeCMurataTSatoCTerayamaYIncrease of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer’s disease and Parkinson’s diseaseLife Sci200577151836184315935398
   PubMed Web of Science ®Google Scholar
• LeeESChenHSolimanKFCharltonCGEffects of homocysteine on the dopaminergic system and behavior in rodentsNeurotoxicology200526336137115935208
   PubMed Web of Science ®Google Scholar
• HeiderILehmensiekVLenkTMüllerTStorchADopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic culturesJ Neural Transm Suppl20046811315354384
   PubMedGoogle Scholar
• HuangGDraganMFreemanDWilsonJXActivation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neuronsGlia2005511475515779086
   PubMed Web of Science ®Google Scholar
• StorchABlessingHBareissMCatechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neuronsMol Pharmacol200057358959410692500
   PubMed Web of Science ®Google Scholar
• KuhnWWoitallaDGerlachMRussHMüllerTTolcapone and neurotoxicity in Parkinson’s diseaseLancet19983529136131313149788488
   PubMed Web of Science ®Google Scholar
• MatsubaraKAoyamaKSunoMAwayaTN-methylation underlying Parkinson’s diseaseNeurotoxicol Teratol200224559359812200190
   PubMed Web of Science ®Google Scholar
• LeeESChenHSolimanKFCharltonCGEffects of homocysteine on the dopaminergic system and behavior in rodentsNeurotoxicology200526336137115935208
   PubMed Web of Science ®Google Scholar
• FusoASeminaraLCavallaroRAD’AnselmiFScarpaSS-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid productionMol Cell Neurosci200528119520415607954
   PubMed Web of Science ®Google Scholar
• CavallaroRAFusoAD’AnselmiFSeminaraLScarpaSThe effect of S-adenosylmethionine on CNS gene expression studied by cDNA microarray analysisJ Alzheimers Dis20069441541916917150
   PubMed Web of Science ®Google Scholar
• HartzCSSchalinskeKLPhosphatidylethanolamine N-methyltransferase and regulation of homocysteineNutr Rev200664(10 Pt 1):46546717063928
   PubMed Web of Science ®Google Scholar
• LiuXXWilsonKCharltonCGEffects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopaLife Sci200066232277228810855949
   PubMed Web of Science ®Google Scholar
• MorrisonLDSmithDDKishSJBrain S-adenosylmethionine levels are severely decreased in Alzheimer’s diseaseJ Neurochem1996673132813318752143
   PubMed Web of Science ®Google Scholar
• MüllerTWoitallaDHauptmannBFowlerBKuhnWDecrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson’s diseaseNeurosci Lett20013081545611445284
   PubMed Web of Science ®Google Scholar
• NagatsuTIsoquinoline neurotoxins in the brain and Parkinson’s diseaseNeurosci Res1997292991119359458
   PubMed Web of Science ®Google Scholar
• AoyamaKMatsubaraKOkadaKN-methylation ability for azaheterocyclic amines is higher in Parkinson’s disease: nicotinamide loading testJ Neural Transm200010789985995
   Web of Science ®Google Scholar
• AoyamaKMatsubaraKKondoMNicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson’s diseaseNeurosci Lett20012981788011154840
   PubMed Web of Science ®Google Scholar
• NaoiMMaruyamaWNakaoNIbiTSahashiKBenedettiMS(R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytesAnn Neurol19984322122169485062
   PubMed Web of Science ®Google Scholar
• MüllerTSallstromBSHaussermannPPlasma levels of R- and S-salsolinol are not increased in “de-novo” Parkinsonian patientsJ Neural Transm199810523239246
   Web of Science ®Google Scholar
• MüllerTSallstromBSHaussermannPPrzuntekHRommelspacherHKuhnWR- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patientsJ Neurol Sci1999164215816210402028
   PubMed Web of Science ®Google Scholar
• BrosnanJTJacobsRLSteadLMBrosnanMEMethylation demand: a key determinant of homocysteine metabolismActa Biochim Pol200451240541315218538
   PubMed Web of Science ®Google Scholar
• BrooksDJSafety and tolerability of COMT inhibitorsNeurology2004621 Suppl 1S39S4614718679
   PubMed Web of Science ®Google Scholar
• DurifFDevauxIPereJJDelumeauJCBourdeixIEfficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end-of-dose deterioration in daily medical practice: an open, multicenter studyEur Neurol200145211111811244274
   PubMed Web of Science ®Google Scholar
• GershanikOEmreMBernhardGSauerDEfficacy and safety of levodopa with entacapone in Parkinson’s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label studyProg Neuropsychopharmacol Biol Psychiatry200327696397114499313
   PubMed Web of Science ®Google Scholar
• GordinAKaakkolaSTeravainenHClinical advantages of COMT inhibition with entacapone – a reviewJ Neural Transm2004111101113431363
   Web of Science ®Google Scholar
• IlliASundbergSOjala-KarlssonPScheininMGordinASimultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactionsEur J Clin Pharmacol19965134273276
   Web of Science ®Google Scholar
• KollerWGuarnieriMHubbleJRabinowiczALSilverDAn open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-offJ Neural Transm2005112222123015503197
   PubMed Web of Science ®Google Scholar
• LarsenJPWorm-PetersenJSidenAGordinAReinikainenKLeinonenMThe tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s diseaseEur J Neurol200310237146
   Web of Science ®Google Scholar
• LyytinenJKaakkolaSAhtilaSTuomainenPTeravainenHSimultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson’s diseaseMov Disord19971244975059251066
   PubMed Web of Science ®Google Scholar
• MartignoniEBlandiniFPacchettiCNappiGCOMT inhibition and safetyFunct Neurol2001164 Suppl13514011996508
   PubMed Web of Science ®Google Scholar
• RinneUKLarsenJPSidenAWorm-PetersenJEntacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study GroupNeurology1998515130913149818851
   PubMed Web of Science ®Google Scholar
• ZijlmansJCDebillyBRascolOLeesAJDurifFSafety of entacapone and apomorphine coadministration in levodopa-treated Parkinson’s disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over studyMov Disord20041991006101115372589
   PubMed Web of Science ®Google Scholar
• MartignoniECosentinoMFerrariMTwo patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphismNeurology200565111820182216344532
   PubMed Web of Science ®Google Scholar
• GrossetKAReidJLGrossetDGMedicine-taking behavior: implications of suboptimal compliance in Parkinson’s diseaseMov Disord200520111397140416092116
   PubMed Web of Science ®Google Scholar
• GrossetKAGrossetDGEffect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trialBMC Neurol200772017634109
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupPramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trialJAMA2000284151931193811035889
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med2000342201484149110816186
   PubMed Web of Science ®Google Scholar